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To determine antimicrobial drug resistance of Strepto-
coccus pneumoniae serotypes, we analyzed isolates from 
blood cultures of sick children residing in the West Bank 
before initiation of pneumococcal vaccination. Of 120 sero-
types isolated, 50.8%, 73.3%, and 80.8% of the bacteremia 
cases could have been prevented by pneumococcal con-
jugate vaccines. Serotype 14 was the most drug-resistant 
serotype isolated. 
S
treptococcus pneumoniae infection is a common cause of 
illness and death worldwide, responsible for an estimated 
1.2 million infant deaths each year (1). The polysaccharide 
capsule is one of the primary virulence factors that contrib-
utes to S. pneumoniae pathogenicity (2). Management of S. 
pneumoniae infections has been complicated by the emer-
gence of multiple antimicrobial drug–resistant strains (3).
Before the introduction of the 7-valent polysaccharide-
protein conjugate vaccine (PCV7), serotypes included in 
this vaccine were responsible for ≈90% of pneumococcal 
infections in children living in industrialized countries; in 
developing countries, coverage has been reported as low as 
26% (4,5). The use of PCV7 reduced the incidence of in-
vasive pneumococcal disease (IPD) in children <5 years of 
age in the United States by 76% (6). However, nonvaccine 
serotypes (i.e., 19A, 6C) have emerged as primary patho-
gens in IPD (7). More recently, the American Advisory 
Committee on Immunization Practices recommended using 
the new Food and Drug Administration–licensed 13-valent 
pneumococcal conjugate vaccine (PCV13), which contains 
the 7 serotypes present in PCV7 and 6 additional serotypes 
(1, 3, 5, 6A, 7F, and 19A).
The Study
In the Palestinian Territories, West Bank, the epidemi-
ology of IPD is not well deﬁ  ned. Our study characterized 
the serotypes and antimicrobial drug resistance patterns 
of 120 consecutive S. pneumoniae isolates collected from 
blood cultures of patients admitted to Caritas Baby Hospi-
tal (n = 113) during January 2001–April 2010 or Maqassed 
Islamic Hospital (n = 7) during January 2009–April 2010. 
Both hospitals are well-equipped and are the major hospi-
tals that perform blood cultures in the West Bank. Blood 
cultures are overused at both institutions; thus, isolated S. 
pneumoniae are representative of circulating serotypes. Be-
cause S. pneumoniae meningitis and invasive pneumonia 
are rare, these IPDs were not included in the study.
Blood cultures were collected from patients suspect-
ed of having sepsis or endocarditis. Criteria for collecting 
blood cultures included leukocytosis with left shift, elevated 
C-reactive protein level, fever, signs of toxicity, hypoten-
sion, and hemodynamic instability. One isolate per patient 
was included in the study. Patients’ ages ranged from 1 day 
to 11 years; most (71.7%) were <2 years of age.
All BACTEC (Becton Dickinson, Sparks, MD, USA)–
positive blood culture samples were placed on 5% sheep 
blood agar, chocolate agar, and MacConkey agar obtained 
from Hy-Laboratories Ltd. (Rehovot, Israel). Suspected S. 
pneumoniae colonies were identiﬁ  ed on the basis of colony 
morphologic appearance, α-hemolysis on 5% sheep blood 
agar, Gram stain appearance, bile solubility, and optochin 
susceptibility. All strains were stored at −80°C until further 
testing.
S. pneumoniae isolates were serotyped by perform-
ing a series of PCRs using primers described by Pai et al 
(8). Because the serotype 6B primer cross-reacts with the 
common 6A cps operon sequence, we did not differentiate 
serotypes 6A/B. 
Of the 120 S. pneumoniae isolates, 117 (97.5%) were 
serotyped; 3 (2.5%) could not be typed. These results are 
similar to those of Pai et al., who successfully typed 95.5% 
of the S. pneumoniae stains by using the same PCR tech-
nique (8). In the West Bank, 20 S. pneumoniae serotypes 
were identiﬁ  ed; serotypes 6A/B, 14, 1, and 9V were the 
predominant strains (online Appendix Table, www.cdc.
gov/EID/content/17/1/94-appT.htm). Overall, 97 (80.8%) 
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of the serotypes are included in PCV13, and >61 (50.8%) 
are covered by PCV7 (6A/B not differentiated).
After serotypes were stratiﬁ   ed by age groups, 86 
(71.7%) S. pneumoniae strains were isolated from children 
<2 years of age; 34 (28.3%) were isolated from children 
>2 years of age. High S. pneumoniae serotype coverage by 
PCV13 was noted for each age group, 77.9% and 76.5%, 
respectively. Conversely, serotype coverage provided by 
PCV7 for each age group was 60.5% and 26.5%, respec-
tively. Of the 6 additional serotypes included in PCV13 and 
not in PCV7, serotypes 1, 3, and 5 appeared to be common 
in our study population. Notably, S. pneumoniae serotype 1 
was not seen in children <2 years of age.
Distribution of the S. pneumoniae serotypes was simi-
lar to that in a study by Fraser et al. in Israeli and in Bed-
ouin children residing in southern Israel (9). However, un-
like the study from southern Israel in which serotypes 1 
and 5 predominated, in this study, serotypes 6A/B and 14 
predominated. Different S. pneumoniae serotype distribu-
tion was also noted when serotypes isolated from the West 
Bank were compared with those from other regional coun-
tries such as Kuwait and Saudi Arabia (10).
Drug susceptibility testing of the different S. pneumo-
niae serotypes was performed by using disk diffusion on 
Mueller-Hinton agar supplemented with 5% sheep blood 
agar for penicillin (oxacillin) (1 μg), erythromycin (15 μg), 
oﬂ  oxacin (5 μg), co-trimoxazole (25 μg), and vancomycin 
(30 μg) according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines (11). In addition, penicillin and 
cefotaxime minimal MICs were determined for all isolates 
by Etest according to the manufacturer’s recommendations 
(AB Biodisk, Solna, Sweden). Interpretation of penicil-
lin and cefotaxime MIC results was performed by using 
the CLSI nonmeningitis guidelines, (parenteral penicillin 
susceptible <2 μg/mL, intermediate 4 μg/mL, resistant >8 
μg/mL, and for cefotaxime susceptible <1 μg/mL, inter-
mediate 2 μg/mL, resistant >4 μg/mL), and the meningitis 
guidelines were applied for penicillin (parenteral penicillin 
susceptible <0.06 μg/mL, resistant >0.12 μg/mL) (11).
 Overall, of the 120 S. pneumoniae blood isolates eval-
uated, 50 (41.7%) were penicillin susceptible; 70 (58.3%) 
were resistant based on the 1-μg oxacillin disk-diffusion 
results. However, MICs for penicillin showed that 118 
(98.3%) isolates were susceptible and only 2 (1.7%) S. 
pneumoniae isolates were intermediately resistant (online 
Appendix Table). These results are similar to those from 
Germany and the United States, which reported low peni-
cillin intermediate rates of 0.2% and 5.6%, respectively 
(12,13). Unlike the absence of resistant isolates in this 
study, both countries reported 1.2% resistance rates.
The small sample size is a limitation in this study and 
mandates caution when comparing the results with those 
of other studies. The use of broth microdilution to deter-
mine penicillin MIC, as reported in the Germany study or 
Etest as performed in this study, has been documented to 
produce comparable results (14). The penicillin resistance 
rate of the S. pneumoniae isolates was higher after apply-
ing the CLSI meningitis guidelines (45.8% sensitive and 
54.2% resistant).
Unlike the low penicillin resistance rate, higher resis-
tance rates were noted for erythromycin and co-trimox-
azole. Of the 120 S. pneumoniae isolates evaluated, 32 
(26.7%) were resistant to erythromycin, and 53 (44.2%) 
were resistant to co-trimoxazole (online Appendix Table). 
After stratifying erythromycin and co-trimoxazole resis-
tance rates by serotype, we showed that serotype 14 had the 
highest resistance rates for both antimicrobial drugs (75%). 
Resistance to >1 agent was noted for 53.3% of the sero-
type 14 isolates (online Appendix Table). S. pneumoniae 
erythromycin resistance in the West Bank differed from 
that in Israel (10%); however, each location had similar co-
trimoxazole (51%) resistance patterns. The spread of the 
co-trimoxazole–resistant clones is alarming because the 
World Health Organization has recommended use of this 
antimicrobial drug for treatment of nonsevere pneumoniae 
in children >2 months of age. No resistance was noted for 
cefotaxime, oﬂ  oxacin, and vancomycin (online Appendix 
Table).
Conclusions
Our study reports the distribution of S. pneumoniae se-
rotypes in blood cultures of children residing in the West 
Bank. This study favors use of PCV13 because 80.8% vac-
cine coverage of the causative serotypes can be achieved 
compared with 50.8% with PCV7. In the West Bank, the 
increased serotype coverage of PCV13 in part results from 
inclusion of S. pneumoniae serotypes 1, 5, and 19A, which 
account for 23.4% of the serotypes not in PCV7. The in-
troduction of PCV13 in the vaccination program will not 
only help reduce the incidence of IPD but will also help 
reduce infections caused by drug-resistant S. pneumoniae 
serotypes, such as serotype 14. Continuous monitoring of 
serotype distribution in this population will ensure that 
available vaccines can provide adequate coverage of circu-
lating pneumococcal serotypes.
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